Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06260774 | Study of TTX-MC138 in Subjects With Advanced Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 16 | — | — | Sep 5, 2024 | Feb 1, 2027 | Oct 2, 2025 | 4 | United States |
The safety and tolerability of escalating dose levels of TTX-MC138 to determine incidence of treatment-emergent adverse events (TEAEs).
proportion of subjects with a best response of CR, PR, or stable disease for at least 8 weeks per RECIST version 1.1.
| Arm | Type | Description |
|---|---|---|
| Dose level 1 | EXPERIMENTAL | 0.4 mg/kg of TTX-MC138 |
| Dose level 2 | EXPERIMENTAL | 0.8 mg/kg of TTX-MC138 |
| Dose level 3 | EXPERIMENTAL | 3.2 mg/kg of TTX-MC138 |
| Name | Type | Description |
|---|---|---|
| TTX-MC138 | DRUG | The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination. |
Inclusion Criteria: 1. Have histologically or cytologically confirmed diagnosis of relapsed/refractory metastatic or locally advanced solid tumor where no standard therapy exists, standard therapy has failed and have no available therapies with known clinical benefit. 2. Must have measurable or eva...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |